LU90341I2 - 75 Ug desogestrel in the absence of ethinyl estradiol (cerazette) - Google Patents

75 Ug desogestrel in the absence of ethinyl estradiol (cerazette)

Info

Publication number
LU90341I2
LU90341I2 LU90341C LU90341C LU90341I2 LU 90341 I2 LU90341 I2 LU 90341I2 LU 90341 C LU90341 C LU 90341C LU 90341 C LU90341 C LU 90341C LU 90341 I2 LU90341 I2 LU 90341I2
Authority
LU
Luxembourg
Prior art keywords
desogestrel
cerazette
absence
ketodesogestrel
regimen
Prior art date
Application number
LU90341C
Other languages
French (fr)
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8205203&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90341(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Publication of LU90341I2 publication Critical patent/LU90341I2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)

Abstract

Disclosed is an oral contraceptive regimen containing daily dosage units each containing from 70 to 80 micrograms of desogestrel, 3-ketodesogestrel or mixtures thereof. It has been found that by making a selection of desogestrel or 3-ketodesogestrel at the described dosages in an oral contraceptive regimen administered over the entire menstrual cycle (e.g. 28 days), effective ovulation inhibition is achieved and intermenstrual bleeding is avoided, while acceptable cycle control is retained. Moreover, the regimen also prevents the formation of persistent ovarian cysts.
LU90341C 1990-12-17 1999-01-27 75 Ug desogestrel in the absence of ethinyl estradiol (cerazette) LU90341I2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP90203371 1990-12-17

Publications (1)

Publication Number Publication Date
LU90341I2 true LU90341I2 (en) 1999-03-29

Family

ID=8205203

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90341C LU90341I2 (en) 1990-12-17 1999-01-27 75 Ug desogestrel in the absence of ethinyl estradiol (cerazette)

Country Status (20)

Country Link
US (1) US5461041A (en)
EP (1) EP0491443B1 (en)
JP (1) JPH04290829A (en)
KR (1) KR100221008B1 (en)
CN (1) CN1036834C (en)
AT (1) ATE135218T1 (en)
AU (1) AU649082B2 (en)
CA (1) CA2057714C (en)
DE (2) DE69117902T2 (en)
DK (1) DK0491443T3 (en)
ES (1) ES2087237T3 (en)
FI (1) FI98984C (en)
GR (1) GR3020180T3 (en)
IE (1) IE71202B1 (en)
LU (1) LU90341I2 (en)
NL (1) NL990003I2 (en)
NO (2) NO178686C (en)
NZ (1) NZ240969A (en)
PT (1) PT99818B (en)
ZA (1) ZA919732B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4133680A1 (en) * 1991-10-11 1993-04-15 Metallgesellschaft Ag STABILIZED STRENGTH, USE OF THE STABILIZED STRENGTH AND METHOD FOR THEIR PRODUCTION
DE4227989A1 (en) * 1992-08-21 1994-06-09 Schering Ag Agent for transdermal application containing 3-keto-desogestrel
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
US6407082B1 (en) * 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
ZA949929B (en) * 1993-12-23 1995-08-23 Akzo Nobel Nv Sugar-coated pharmaceutical dosage unit.
DE4405590C1 (en) * 1994-02-22 1995-07-20 Hesch Rolf Dieter Prof Dr Med Postmenopausal hormone treatment
DK0782449T3 (en) * 1994-09-22 2003-08-04 Akzo Nobel Nv Process for preparing dosage units by wet granulation
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
WO1999051214A2 (en) * 1998-04-07 1999-10-14 Akzo Nobel N.V. Progestogen-only contraceptive kit
AU5619399A (en) * 1998-08-11 2000-03-06 Akzo Nobel N.V. Progestogen-only contraceptive kit providing good cycle control
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
GB0114746D0 (en) 2001-06-16 2001-08-08 Boots Co Plc Medicinal composition
US6574033B1 (en) 2002-02-27 2003-06-03 Iridigm Display Corporation Microelectromechanical systems device and method for fabricating same
TW200403075A (en) * 2002-05-29 2004-03-01 Akzo Nobel Nv Progestagenic dosage units
BRPI0409860A (en) * 2003-04-29 2006-05-16 Akzo Nobel Nv anti-solvent solidification process
DE102005053771A1 (en) * 2005-11-09 2007-05-10 Grünenthal GmbH Dosage form for hormonal contraception
DE202010010589U1 (en) 2010-07-22 2010-10-14 Bayer Schering Pharma Aktiengesellschaft Estrogen-free formulation for oral contraception, preferably usable for women with conscious / unconscious lactose intolerance or with deliberate lactose-free contraception
EP2730284A1 (en) * 2012-11-12 2014-05-14 Naari AG Levonorgestrel-only-composition for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
WO2017000081A1 (en) * 2015-06-30 2017-01-05 上海交通大学 Applications of etonogestrel in preparation of products for resisting against prostate cancer
US11679114B2 (en) 2021-07-26 2023-06-20 Navad Life Sciences Pte Progestogen-only oral contraception

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4066757A (en) * 1973-03-26 1978-01-03 Ortho Pharmaceutical Corporation Oral contraceptive regimen
ATE86484T1 (en) * 1987-08-08 1993-03-15 Akzo Nv CONTRACEPTIVE IMPLANT.

Also Published As

Publication number Publication date
NO2002013I2 (en) 2007-02-26
DK0491443T3 (en) 1996-06-24
AU649082B2 (en) 1994-05-12
GR3020180T3 (en) 1996-09-30
CA2057714A1 (en) 1992-06-18
NL990003I2 (en) 1999-05-03
ATE135218T1 (en) 1996-03-15
EP0491443B1 (en) 1996-03-13
FI915913A (en) 1992-06-18
NO178686B (en) 1996-02-05
AU8967891A (en) 1992-06-18
FI915913A0 (en) 1991-12-16
NL990003I1 (en) 1999-04-01
KR100221008B1 (en) 1999-09-15
EP0491443A1 (en) 1992-06-24
JPH04290829A (en) 1992-10-15
PT99818B (en) 1999-05-31
IE914271A1 (en) 1992-06-17
DE19975011I2 (en) 2005-05-04
ZA919732B (en) 1992-09-30
NO914970D0 (en) 1991-12-16
NO178686C (en) 1996-05-15
CN1062465A (en) 1992-07-08
PT99818A (en) 1992-11-30
DE69117902D1 (en) 1996-04-18
FI98984C (en) 1997-09-25
KR920011514A (en) 1992-07-24
CN1036834C (en) 1997-12-31
US5461041A (en) 1995-10-24
DE69117902T2 (en) 1996-08-29
CA2057714C (en) 2002-10-01
NO914970L (en) 1992-06-18
IE71202B1 (en) 1997-02-12
NZ240969A (en) 1994-04-27
FI98984B (en) 1997-06-13
ES2087237T3 (en) 1996-07-16

Similar Documents

Publication Publication Date Title
LU90341I2 (en) 75 Ug desogestrel in the absence of ethinyl estradiol (cerazette)
LU90634I2 (en) Gestodene and ethinylestradiol / minesse
NZ234051A (en) Treating post-menopausal disorders using an estrogenic compound mixed with a compound having progestational activity
IL122109A0 (en) A two-stage pharmaceutical preparation for hormonal contraception and a kit containing the same
AU1921997A (en) Contraceptive process and kit for female mammals that consists of a combination of gestagen and estrogen
NZ333750A (en) Monophasic contraceptive method and kit comprising a combination of a progestin and estrogen